Skip to main content
. 2020 May 18;5(Suppl 3):e000804. doi: 10.1136/esmoopen-2020-000804

Table 5.

Priorities for pancreatic cancer: medical oncology in advanced/metastatic disease

High priority Medium priority Low priority
First line chemotherapy in patients fit for a combined regimen likely to improve survival and quality of life outcomes in metastatic disease In case of asymptomatic or pauci-symptomatic elderly patients consider with caution the risk/benefit ratio derived from monotherapy treatment Follow-up imaging and restaging studies in asymptomatic patients
Continuation of treatment in the context of a clinical trial Consider with caution starting or prosecution of second line treatment according to the patient’s condition Antiresorptive therapy (zoledronic acid, denosumab) that is not needed urgently for hypercalcaemia